Work

Supplementary Table 1 from Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Year: 2023

Type: supplementary-materials

Abstract: Adverse events with maximum grade seen

DOI: 10.1158/1078-0432.22482596.v1

Authors: Christos Fountzilas, David L. Bajor, Sarbajit Mukherjee, Joel Saltzman, Agnieszka K. Witkiewicz, Orla Maguire, Hans Minderman, Ram Nambiar, Hanna R. Rosenheck, Erik S. Knudsen, Jason B. Muhitch, Scott I. Abrams, Chong Wang, Alan D. Hutson, Kristopher Attwood, Karen A. Hicks, Jennifer A. Jurcevic, Pawel Kalinski, Renuka Iyer, Patrick M. Boland

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361940183

Cites:

Cited by:

Related to: 10